Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors

a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

International Guideline Harmonization Group ototoxicity group

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

Original languageEnglish (US)
Pages (from-to)e29-e41
JournalThe Lancet Oncology
Volume20
Issue number1
DOIs
StatePublished - Jan 1 2019

Fingerprint

Young Adult
Guidelines
Platinum
Hearing Loss
Radiotherapy
Head
Neoplasms
Language Development
Tinnitus
Brain
Practice Guidelines
Learning
Drug Therapy
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

@article{3c95fdc9a7e94cef8017bf274429b7b7,
title = "Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium",
abstract = "Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.",
author = "{International Guideline Harmonization Group ototoxicity group} and Eva Clemens and {van den Heuvel-Eibrink}, {Marry M.} and Mulder, {Ren{\'e}e L.} and Kremer, {Leontien C.M.} and Hudson, {Melissa M.} and Roderick Skinner and Constine, {Louis S.} and Bass, {Johnnie K.} and Kuehni, {Claudia E.} and Thorsten Langer and {van Dalen}, {Elvira C.} and Edith Bardi and Bonne, {Nicolas Xavier} and Brock, {Penelope R.} and Beth Brooks and Bruce Carleton and Eric Caron and Chang, {Kay W.} and Karen Johnston and Kristin Knight and Nathan, {Paul C.} and Etan Orgel and Prasad, {Pinki K.} and Jan Rottenberg and Katrin Scheinemann and {de Vries}, {Andrica C.H.} and Thomas Walwyn and Annette Weiss and {am Zehnhoff-Dinnesen}, Antoinette and Cohn, {Richard J.} and Wendy Landier",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/S1470-2045(18)30858-1",
language = "English (US)",
volume = "20",
pages = "e29--e41",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors

T2 - a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

AU - International Guideline Harmonization Group ototoxicity group

AU - Clemens, Eva

AU - van den Heuvel-Eibrink, Marry M.

AU - Mulder, Renée L.

AU - Kremer, Leontien C.M.

AU - Hudson, Melissa M.

AU - Skinner, Roderick

AU - Constine, Louis S.

AU - Bass, Johnnie K.

AU - Kuehni, Claudia E.

AU - Langer, Thorsten

AU - van Dalen, Elvira C.

AU - Bardi, Edith

AU - Bonne, Nicolas Xavier

AU - Brock, Penelope R.

AU - Brooks, Beth

AU - Carleton, Bruce

AU - Caron, Eric

AU - Chang, Kay W.

AU - Johnston, Karen

AU - Knight, Kristin

AU - Nathan, Paul C.

AU - Orgel, Etan

AU - Prasad, Pinki K.

AU - Rottenberg, Jan

AU - Scheinemann, Katrin

AU - de Vries, Andrica C.H.

AU - Walwyn, Thomas

AU - Weiss, Annette

AU - am Zehnhoff-Dinnesen, Antoinette

AU - Cohn, Richard J.

AU - Landier, Wendy

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

AB - Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

UR - http://www.scopus.com/inward/record.url?scp=85059341149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059341149&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30858-1

DO - 10.1016/S1470-2045(18)30858-1

M3 - Review article

VL - 20

SP - e29-e41

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 1

ER -